Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1)

Hays, Sean M. and Aylward, Lesa L. (2008) Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1). Regulatory Toxicology and Pharmacology, 51 3 SUPPL.: S57-S67. doi:10.1016/j.yrtph.2008.05.010


Author Hays, Sean M.
Aylward, Lesa L.
Title Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1)
Journal name Regulatory Toxicology and Pharmacology   Check publisher's open access policy
ISSN 0273-2300
1096-0295
Publication date 2008-08
Sub-type Article (original research)
DOI 10.1016/j.yrtph.2008.05.010
Open Access Status Not yet assessed
Volume 51
Issue 3 SUPPL.
Start page S57
End page S67
Total pages 11
Place of publication Maryland Heights, MO, United States
Publisher Academic Press
Language eng
Formatted abstract
Recent efforts by the US Centers for Disease Control and Prevention and other researchers have resulted in a growing database of measured concentrations of chemical substances in blood or urine samples taken from the general population. However, few tools exist to assist in the interpretation of the measured values in a health risk context. Biomonitoring Equivalents (BEs) are defined as the concentration or range of concentrations of a chemical or its metabolite in a biological medium (blood, urine, or other medium) that is consistent with an existing health-based exposure guideline. This document reviews available pharmacokinetic data and models for acrylamide and applies these data and models to existing health based exposure guidance values from the US Environmental Protection Agency, the Agency for Toxic Substances and Disease Registry, Health Canada, and the World Health Organization, to estimate corresponding BE values for acrylamide in blood and urine. Specifically, BEs are calculated for AA hemoglobin valine terminal adducts [N-(2-carbamoylethyl)valine (AAVal)] and GA hemoglobin valine terminal adducts [N-(2-carbamoyl-2-hydroxyethyl)valine (GAVal)], and the AA glutathione conjugate N-acetyl-S-(2-carbamoylethyl)cysteine (AAMA) in urine. These values can be used as screening tools for evaluation of biomonitoring data for acrylamide in the context of existing risk assessments for acrylamide and for prioritization of the potential need for additional risk assessment and risk management efforts for acrylamide.
Keyword Acrylamide
BEs
Biomonitoring Equivalents
Blood
Risk assessment
Screening
Urine
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: National Research Centre for Environmental Toxicology Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 15 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 24 Mar 2016, 11:21:12 EST by System User on behalf of Learning and Research Services (UQ Library)